Transitional cell carcinomas (TCCs) have been classified into two groups with distinct clinical behavior and different molecular profiles. Low-grade tumors are always papillary and usually superficial, whereas high-grade tumors can be either papillary or nonpapillary and are often invasive. Patients diagnosed with localized TCC have a 5-year relative survival rate of 93%. However, patients presenting with regional and distant disease spread have 5-year relative survival rates of 49% and 6%, respectively.
Transitional cell carcinomas (TCCs) have been classified into two groups with distinct clinical behavior and different molecular profiles. Low-grade tumors are always papillary and usually superficial, whereas high-grade tumors can be either papillary or nonpapillary and are often invasive. Patients diagnosed with localized TCC have a 5-year relative survival rate of 93%. However, patients presenting with regional and distant disease spread have 5-year relative survival rates of 49% and 6%, respectively. 1 Bladder cancer progression and development of secondary metastases follow complex sequential steps characterized by alterations of many genes involved in critical cell functions, definitively not being completely understood. 2 It has been reported that genes on chromosome 6 could regulate expression of metastasis suppressor genes encoded elsewhere within the genome. [3] [4] [5] [6] [7] [8] KiSS-1, mapping to chromosome 1q32, 8 is one of these genes regulated at chromosome 6. KiSS-1 expression was discovered to be reduced in metastatic melanoma. [3] [4] [5] [6] Experimental and clinical studies have revealed its role as a functionally active metastasis suppressor gene in certain tumors. [5] [6] [7] [8] [9] Regulation of events downstream of cell-matrix adhesion involving cytoskeleton reorganization has been attributed to KiSS-1.
7,10 -14 However, the mechanism by which KiSS-1 is involved in the invasive/metastatic phenotype has not been elucidated. A differential expression of KiSS-1 and a clone representing the regulatory counterpart of KiSS-1 on chromosome 6 3,4 were identified through molecular profiling analysis of bladder cancer cell lines and primary bladder tumors. We further evaluated the role of KiSS-1 in bladder cancer progression by characterizing its mRNA expression levels in a comprehensive collection of bladder cancer cell lines, as well as in normal urothelium, and in a large cohort of bladder tumors.
Materials and Methods

Cell Culture and RNA Extraction Preparation of cDNA Microarrays
Two separate studies of expression profiling in bladder cancer on bladder cancer cell lines and clinical material using different sets of cDNA microarrays were performed. First, a set of 8976 sequence-verified human IMAGE cDNA clones, representing both known genes and expressed sequence tags, was used to compare the expression profiles of nine bladder cancer cell lines (T24, J82, 5637, HT-1376, RT4, SCaBER, TCCSUP, UMUC-3, and HT1197) against a pool containing equal RNA quantities of each of them. The second set contained 17,842 known genes and expressed sequence tags and was used to study the transcriptome of 15 bladder cancer tumors against a pool containing equal RNA quantities of four selected bladder cancer cell lines: T24, J82, RT4, and HT1197. Clones were polymerase chain reaction amplified and spotted onto poly-L-lysine-coated microscope slides using a custom robot designed and built at Albert Einstein College of Medicine, New York, NY (sequence.aecom.yu.edu/bioinf/funcgenomic.html). 15 
Labeling of cDNA, Hybridization to Arrays, Image Acquisition, and Normalization of the cDNA Microarrays
In the first gene expression analysis of the bladder cancer cell lines, 10 g of total RNA of each cell line was labeled with Cy5 and hybridized against 10 g of total RNA of a pool containing equal RNA quantities of each of these cell lines labeled with Cy3. 16 In the expressionprofiling study of the bladder tissues, 5 g of total RNA of each bladder tissue and pool of cell lines was linearly amplified using a single amplification round. 17 Amplified cRNA obtained from bladder tissues (normal or tumor) were labeled with Cy5 and hybridized against amplified cRNA obtained from a pool containing equal RNA quantities of the four cell lines labeled with Cy3. After hybridization, slides were washed, dried, and scanned by an Axon automated laser scanner. GenePix software was used for gridding and calculation of red and green signal intensities. 18 Before any analysis, plots of the fold change versus the average intensity were examined to look for abnormalities in single-array data. Samples were normalized using this intensity-dependent normalization using the Splus function lowess. 19 We focused on the expression results in these two independent studies of two clones representing KiSS-1 and 6q16.2-21, whose accession numbers were AA464595 and N76881, respectively. We collected the red to green ratio (R/G) expression data of these two clones for the analysis of this study.
Clinical Evaluation of the Expression of KiSS-1
Tissue Samples and Microarrays
Twenty-five paired normal urothelium and respective bladder tumors were first evaluated. All these tumors presented high tumor grade. Three different bladder cancer microarrays also were constructed for this study. All these specimens were obtained under Institutional Review Board-approved protocols. Normal and tumor tissues were embedded in paraffin and 5-m sections were stained with hematoxylin and eosin to identify viable, morphologically representative areas of the specimen from which needle core samples were taken, using a precision instrument (Beecher Instruments, Silver Spring, MD). From each specimen triplicate cores with diameters of 0.6 mm were punched and arrayed on the recipient paraffin block. 20 Five-m sections of these tissue array blocks were cut and placed on charged poly-L-lysinecoated slides and used for in situ hybridization analysis.
These tissue microarrays included a total of 173 bladder primary TCC tumors. Tumor stage and grade were defined according to consensus criteria. 21, 22 A total of 40 superficial (TIS, pTa, T1) and 64 invasive (pT2, pT3, pT4) TCC tumors were analyzed in two microarrays. These tumors corresponded to 14 grade 1, 8 grade 2, and 82 grade 3 lesions. The third tissue microarray comprised a cohort of 69 well-characterized bladder primary TCC cases with known p53 and pRB status, and consisted of two superficial (TIS, pTa, T1) and 67 invasive lesions (pT2, pT3, pT4).
In Situ Hybridization
Human KiSS-1 cDNA sequence (GenBank accession number, AA464595) was obtained from the set of clones used in the cDNA microarrays. Recombinant plasmid (1 g) was linearized by EcoRI and NotI. Riboprobes were generated with T7 and T3 polymerases for 2 hours at 37°C in 1ϫ transcription buffer (Boehringer Mannheim, Indianapolis, IN) containing 20 U of RNase inhibitor; 1 mmol/L each of ATP, GTP, and CTP; 6.5 mmol/L of UTP; and 3.5 mmol/L of digoxigenin-UTP. Deparaffinized tissue sections were rinsed in water and phosphate-buffered saline for 10 minutes. Slides were digested in prewarmed in citrate buffer (pH ϭ 6) for 5 minutes in microwave at full power. Prehybridization was performed for 30 minutes at 45°C in 50% deionized formamide and 2ϫ standard saline citrate. For hybridization, 10 pmol/L of digoxigenin-labeled riboprobe was added to 50 l of hybridization buffer [50% deionized formamide (v/v), 10% dextran sulfate, 2ϫ standard saline citrate, 1% sodium dodecyl sulfate, and 0.25 mg/ml of herring sperm DNA]. After overnight incubation at 45°C, slides were washed twice for 20 minutes in prewarmed 2ϫ standard saline citrate at 42°C, followed by two washes in prewarmed 1ϫ standard saline citrate at 42°C for 20 minutes. Slides were then incubated in normal sheep serum diluted in buffer 1 (2 mol/L Tris-HCl, 5 mol/L NaCl, pH 7.5) for 30 minutes followed by incubation in the same buffer with antibody digoxigenin-AP (Boehringer Mannheim) at a dilution of 1:500 for 2 hour at room temperature. Visualization was accomplished by nitro blue tetrazolium 5-bromo-4-chloro-3-indolylphosphate. The slides were counterstained with methyl green and mounted.
Immunohistochemistry
Protein patterns of expression of p53, pRB, and certain adhesion molecules were assessed at the microanatomical level, using both cytospin from all cell lines and tissue samples outlined above. Standard immunoperoxidase procedures were used for immunohistochemistry. The following antibodies were used: E-cadherin, mouse monoclonal clone 36 at 1:1000 (2.5 g/ml) (BD Transductions Labs, Lexington, KY); moesin, mouse monoclonal clone 38/87 at 1:50 (4 g/ml) with microwave pretreatment of the slides (Neomarkers, Fremont, CA); zyxin, mouse monoclonal clone 21 at 1:25 (10 g/ml) with microwave pretreatment of the slides (Transduction Labs); underphosphorylated pRB, mouse monoclonal clone G99-549 at a final concentration of 10 g/ml (PharMingen, San Diego, CA); total RB, mouse monoclonal clone 3C8 at a final concentration of 1.2 g/ml (QED Bioscience, San Diego, CA); p53 mouse monoclonal clone 1801 at 0.2 g/ml (Calbiochem, Cambridge, MA); p21/ WAF1, mouse monoclonal Ab-1 at 5 g/ml (Calbiochem); cyclin D1, mouse monoclonal 1 g/ml (Calbiochem); cyclin E, purified rabbit antiserum (1:500, supplied as a tissue culture supernatant by Dr. A. Koff, Memorial SloanKettering Cancer Center). Staining conditions were optimized on sections from formalin-fixed, paraffin-embedded tissue controls for each antibody as specified by manufacturers. Antibody reactivity was detected by using diaminobenzidine as chromogen, and sections were counterstained with hematoxylin. The primary antibody was omitted for negative controls.
Data Analysis
All TCCs (n ϭ 173) were used for the analysis of association between KiSS-1 p53, pRB, and other cellcycle and adhesion molecules evaluated by immunohistochemistry. These cases were also used for evaluating KiSS-1 mRNA expression versus histopathological stage and tumor grade, using the nonparametric WilcoxonMann-Whitney and Kruskall-Wallis tests. 24 The consensus value of the three representative cores from each tumor sample arrayed was used for statistical analyses. KiSS-1 expression values were displayed as negative to low (0 to 20%), intermediate (20 to 40%), and high (Ͼ40%). These cutoffs were selected to represent low different degrees of expression of KiSS-1.
The prognostic value of the ratios of KiSS-1 and 6q16.2-21 was evaluated in the subsets of 15 patients to whom cDNA microarray analysis were performed. The relationship of the in situ hybridizations of KiSS-1 to outcome was also evaluated using a subset of 69 TCC cases for which follow-up was available. Specific of disease overall survival time was defined as the months elapsed between transurethral resection (two superficial lesions) or cystectomy (rest of cases) and death from disease (or the last follow-up date). Patients who were alive at the last follow-up or lost to follow-up were censored. For survival analysis of the patients to whose tumors expression profiles were analyzed using cDNA microarrays, ratios of KiSS-1 and 6q16.2-21 and mRNA levels of KiSS-1 were analyzed as categorical variables taking the cutoffs of 1.5 and 4.0, respectively. When we evaluated the prognostic value of the mRNA levels of KiSS-1 obtained by in situ hybridization on the cohort of 69 patients, we used the expression cutoff of 40% to define the expression of KiSS-1 as high or positive. This cutoff was selected to represent low and high degrees of expression of KiSS-1. The association of the KiSS-1 expression levels with overall survival was analyzed using the log-rank test. Survival curves were plotted using standard Kaplan-Meier methodology. 24 Associations between biomarkers were analyzed using Kendall's tau test using the SPSS statistical package (version 8.0).
Cell Sorting
Cells were grown and collected with trypsin at 80% confluency. They were washed with phosphate-buffered saline and stained with Hoechst 33342 for 2 hours at 37°C. Cell cycle subpopulations G 1 , S, and G 2 M were sorted using a MoFlow sorter. Cytospins of each cell cycle phase were fixed with methanol:acetone (1:1 v/v) during 10 minutes at Ϫ20°C and kept at Ϫ80°C until the analysis of KiSS-1 by in situ hybridization.
Results
Experimental Design
The present analysis was conducted under four major sets of experiments. Initially, bladder cancer cell lines and primary bladder tumor samples were analyzed using cDNA microarrays and KiSS-1 was identified as a differentially expressed gene between distinct histopathological tumor types and stages of the disease. Paired normal urothelium and tumor were evaluated to assess the potential involvement of KiSS-1 in the progression of the disease. Third, tissue microarrays were used to validate the potential clinical significance of KiSS-1 at the microanatomical detail using in situ hybridization on tissue samples of well-characterized cases. A cohort of superficial and invasive bladder neoplasms was used to evaluate the association between KiSS-1 with histopathological stage and grade. An additional tissue microarray, containing bladder tumors from cases with annotated follow-up, was used to delineate associations of KiSS-1 with clinical outcome. Finally, KiSS-1 expression along cell cycle was explored using cytospins containing enriched cell-cycle populations of the bladder cancer cell lines under study obtained by sorting analysis.
Identification of a Differential Expression of KiSS-1 in Bladder Cancer Using cDNA Microarrays
We identified differential expression of KiSS-1 in bladder cancer in two independent profiling approaches. First, the expression profiling of nine bladder cancer cell lines: T24, J82, 5637, HT-1376, RT4, SCaBER, TCCSUP, UMUC-3, and HT1197, was compared against a pool containing equal RNA quantities of each of them using cDNA arrays containing 8976 clones. This analysis revealed low expression of KiSS-1 in most of the cell lines derived from the most advanced bladder carcinomas as compared to the ones obtained from a papillary tumor (RT4) ( Table 1) .
The expression profiles of 15 bladder cancer tumors was analyzed versus a pool containing equal RNA quantities of four selected bladder cancer cell lines: T24, J82, RT4, and HT1197 using cDNA microarrays containing 17,842 known genes and expressed sequence tags (Table 1). We observed that transcripts of KiSS-1 were highly expressed in superficial noninvasive tumors when compared to organ-confined invasive and primary invasive TCCs of patients that developed metastatic lesions (Table 2). We also observed that messenger expression levels of the 6q16.2-21 clone displayed similar variations as the KiSS-1 gene in both tumor cell lines and clinical samples analyzed (Tables 1 and 2) .
We evaluated whether the expression ratios of KiSS-1 and 6q16.2-21 obtained from the cDNA microarray analysis of the patients with bladder tumors could provide additional predictive information. The overall survival analysis revealed that KiSS-1 ratios were significantly associated with overall survival in this subset of 15 bladder lesions (Figure 1 ). Patients whose tumor samples were subjected to gene profiling had a median follow-up of 12 months (mean, 14.3 months; range, 1 to 44 months) ( Table 2) . We further investigated the prognostic utility of KiSS-1 for overall survival in a separate set of patients with bladder cancer (see below).
KiSS-1 Expression Studies in Normal Urothelium and Bladder Tumors
The differential expression of KiSS-1 in the progression of bladder cancer was evaluated in 25 paired normal urothelium and respective bladder tumors. High positive expression of KiSS-1 was observed in all normal urothelium samples ( Figure 2 ). All superficial tumors showed intermediate or high expression of KiSS-1. Three invasive patients displayed intermediate expression of KiSS-1, whereas undetectable to low expression was observed in 80% (14 of 17) of the invasive tumors. All primary bladder tumors that developed distant metastases showed complete loss of KiSS-1. KiSS-1 expression levels between superficial and invasive tumors were found to reach a significant association (Mann-Whitney, P ϭ 0.001). All these tumors presented high tumor grade. We evaluated the potential correlation between KiSS-1 expression and the suspicion of vascular invasion, positive nodes, multifocality, squamous differentiation, and carcinoma in situ (Table 3) . Interestingly, we only observed a significant association of KiSS-1 expression with those patients in which vascular invasion was reported (Mann-Whitney, P ϭ 0.012).
We studied the potential role of KiSS-1 expression to identify patients with superficial and invasive disease. KiSS-1 expression was analyzed by in situ hybridization in primary tumors spotted onto the superficial and invasive tissue microarrays. The majority of superficial tumors displayed high expression of KiSS-1 in 20 of 32 (62.5%) of the cases. In contrast, intermediate or undetectable levels of KiSS-1 were detected in 56.1% of the invasive tumors. KiSS-1 expression was significantly associated with stage (Mann Whitney, P ϭ 0.031) and not with tumor grade in our series ( Table 4) .
The association of the expression of KiSS-1 with overall survival was evaluated in a subset of 69 bladder tumors spotted onto a tissue microarray whose follow-up was available. There were 16 patients that displayed a KiSS-1 expression lower than 20% in this series. Their mean survival time was 14.7 months (95% CI, 8.9 to 20.4) with a median survival time of 9.0 months. Only one patient (6.25%) was alive among those tumors showing less than 20% in KiSS-1. Patients showing expression of KiSS-1 higher than 20% showed a mean survival time was 47.3 months (95% CI, 33.5 to 61.2) with a median survival time of 37.0 months. In this case, 23 of 48 patients showing KiSS-1 higher than 20% were censored alive (47.92%). KiSS-1 expression reached a significant association with overall survival (Figure 3) . We also observed that all bladder tumors developing distant metastases showed a complete loss of KiSS-1 within this cohort of follow-up patients.
We evaluated the association of KiSS-1 expression with a selected group of genes previously reported to be altered during bladder cancer progression, including p53, total and underphosphorylated retinoblastoma, cyclin E, p21, moesin, zyxin, and E-cadherin. Immunohistochemical expression levels of these proteins were characterized in the bladder tumors contained in our tissue microarrays. The loss of KiSS-1 expression was significantly associated with total retinoblastoma (P ϭ 0.034, n ϭ 142) and E-cadherin expression (P ϭ 0.002, n ϭ 144). Thus, the expression of KiSS-1 was associated with the phosphorylation status of pRB and altered expression of adhesion E-cadherin.
Expression of KiSS-1 along Cell Cycle
We were interested in evaluating the potential association of KiSS-1 expression along cell cycle. The expression of KiSS-1 was evaluated on cytospins by in situ hybridization containing each cell cycle phase-enriched population obtained by sorting analysis of each of the cell lines under study. We noted a differential expression of KiSS-1 among samples in accordance with the expression levels obtained by the DNA analysis. We confirmed that the differential expression of KiSS-1 among the various bladder tumor cells lines analyzed by Northern blotting and quantitative reverse transcriptase-polymerase chain reaction (data not shown). However, we did not observe any significant differential messenger expression of KiSS-1 among the cell-cycle cytospins (Figure 4 ).
Discussion
Expression profiles analyses using cDNA microarrays identified in this study a differential expression of KiSS-1 in bladder cancer, providing clinical information of added predictive nature. KiSS-1 expression was high in normal urothelium, while transcript levels of KiSS-1 were shown to be associated with stage and grade in primary bladder cancer. Moreover, undetectable to low KiSS-1 expression was related to survival when validated in tissue microarrays containing primary bladder tumors.
The advent of high-throughput methods of molecular analysis is allowing the further characterization of distinct gene expression profiles of specific tumor subtypes. 25, 26 The use of cDNA microarrays aims at identifying prevalent and potentially clinically relevant alterations within human tumors. In this study, the combination of cDNA and tissue microarray validation addressed the relevance of the KiSS-1 in bladder cancer. This combination of technologies has been shown to accelerate molecular studies that seek associations between genetic and epigenetic molecular changes and clinicopathological variables, including patient outcome. The present study was initiated based on the differential gene expression of the KiSS-1 gene in bladder cancer in two cDNA expression analyses. The first set of data were obtained by comparing each of nine bladder cancer cell lines against their 
NT, No tumor was detected in one of the patient specimens. However, the specimen analyzed lacking tumor cells showed a positive expression of KiSS-1. pool, representing an optimal approach for comparing the expression levels of KiSS-1 of each of the cell lines, because each of them was considered in the reference. Interestingly, the two bladder cancer cells derived from low-stage (RT4) or low-grade (5637) tumors showed the highest ratios of KiSS-1 and 6q16.2-21. These observations were then followed by the analyses of a second set of data obtained by the study of expression profiles of normal urothelium and clinical tumor samples representative of different stages of the disease. We observed that tumors displayed lower transcript levels of KiSS-1 gene as compared to normal urothelium. A minimum of 75% enrichment of tumor cells was granted by macrodissection of the primary clinical samples before RNA extraction. Based on the lack of expression of KiSS-1 in stromal elements, such as fibroblasts, we believe that the expression ratios of KiSS-1 obtained in the cDNA expression profiling account specifically for the tumor cells. The loss of KiSS-1 expression in bladder tumors as compared to their paired normal urothelium may support an involvement of this gene in bladder cancer progression. We have observed a highly positive messenger expression of KiSS-1 in superficial tumors including all pT1 lesions. This observation together with the finding that many of the invasive tumors already show partial or complete loss in KiSS-1 expression, and that primary tumors from all patients developing distant metastasis showed a KiSS-1 loss, support that KiSS-1 might have a tumor suppressor role and be a late event in the progression of the disease. Based on these results, it cannot be discarded that KiSS-1 might be related to the development of distant metastasis, as per the metastasis suppressor role already reported in melanoma, 4, 5 and suggested also in other human cancers such as breast cancer 7 or thyroid tumors. 9 Moreover, this differential expression was associated with histopathological criteria and, more interestingly with clinical outcome.
KiSS-1 gene maps to 1q32-q41, 8 a region frequently deleted in certain tumors, including melanoma. In the present study, it is interesting to note that not only KiSS-1 was found differentially expressed, but also clones representing the regulatory chromosomal counterpart in chromosome 6, had similar changes. 27 We observed that ratios of KiSS-1 correlated with those of 6q16.2-21 in the bladder cancer cell lines and the tumor samples under cDNA analysis. This is an interesting observation, offering mechanistic support for the involvement of KiSS-1 in bladder cancer progression and suggesting a potential tumor suppressor role for KiSS-1. Moreover, aberrations, deletions, and loss of heterozygosity in chromosome 6 have been reported to be frequent in late-stage bladder tumors. 28 -30 The lack of suitable antibodies can slow down the performance of more extensive clinical studies for KiSS-1 at the microanatomical level by immunohistochemistry. In this regard, the analysis by in situ hybridization has allowed us to circumvent this deficiency to study clinical material. KiSS-1 expression has been evaluated by Northern blot analysis in several tissues, including heart, brain, liver, lung, skeletal muscle, kidney, pancreas, and placenta. 6 To our knowledge, this is the first report of the expression of KiSS-1 in the urothelium.
The mechanism by which KiSS-1 is involved in the invasive/metastatic phenotype has not been completely elucidated. Biologically, the inactivation of the key regulatory RB1 and TP53 pathways has been shown to be necessary for bladder cancer development and progression. [31] [32] [33] We evaluated whether KiSS-1 expression was related to molecular targets of these known pathways, including p53, p21, and RB. 29 -34 Based on the believed involvement of KiSS-1 to regulate events downstream of cell-matrix adhesion, independent or not to cytoskeleton reorganization, 7, 9 we incorporated to the analysis data set related to adhesion proteins already studied in this cohort of patients, including moesin, zyxin, and E-cadherin. We observed that the loss of KiSS-1 expression was present in those patients that had also lost membrane E-cadherin expression, a gene described to display a metastasis suppressor role in several tumors, including breast 35 and bladder cancer. 36 This observation may indicate a cooperative involvement of KiSS-1 and E-cadherin in the suppression of metastatic potential of bladder tumors. KiSS-1 might function as an upstream regulator of adhesion molecules such as E-cadherin. 14 The association found between expression of KiSS-1 and the inactive hyperphosphorylated pRB products (total pRB), critical in the G 1 /S transition, 34 led us to investigate the variation of KiSS-1 messenger expression along the cell cycle. We generated cytospins containing enriched subpopulations of the distinct cell-cycle phases of the bladder cancer cell lines under investigation. However, there was no association between KiSS-1 expression and cell-cycle phases in the bladder cancer cell lines analyzed. To our knowledge, this is the first report on expression of KiSS-1 along cell cycle in bladder cancer cells. The expression levels of KiSS-1 in T24 that we have observed by cDNA microarray analysis and in situ hybridization are consistent with a report evaluating its mRNA expression in T24, one of the bladder cancer cell lines that we have incorporated in our study. 37 Overall, gene expression profiling identified the potential involvement of KiSS-1, a novel molecular target in bladder cancer. The loss of its messenger expression was related to tumor stage and grade when validated in human tissue microarrays containing primary bladder tumors. It was also shown to be associated with pRB and adhesion networks, suggesting a mechanistic support for its involvement in the progression of the disease. The potential tumor suppressor role of KiSS-1 in bladder cancer suggested in our results requires further investigation. Most importantly, KiSS-1 was shown to be of clinical relevance by the predictive nature of its loss of expression with the outcome of patients with bladder cancer.
